Colterol is a beta-2 adrenoreceptor agonist. Bitolterol, a diester prodrug of colterol, was marketed by Elan Pharmaceuticals for the treatment of reversible bronchospasm associated with asthma or chronic obstructive pulmonary diseases.

Daiichi Sankyo developed an inhibitor of acyl-coenzyme A:cholesterol acyltransferases (ACAT1 and ACAT2), pactimibe (also known as CS 505). Pactimibe has been used in trials phase II for reducing the progression of coronary artery disease and in patients with atherosclerosis. However, on October 26, 2005, the company made the decision to discontinue all ongoing clinical studies of pactimibe, because of the secondary endpoints that showed a lower effect of the drug on atherosclerosis than the standard of care alone and no beneficial effect on the frequency of cardiovascular events.

Cefempidone is a broad-spectrum cephalospolin antibiotic

Sabiporide was developed as a specific Na(+)/H(+) exchanger (NHE1) inhibitor. Sabiporide possessed a cardioprotective effect that was shown in a preclinical model of myocardial infarction in the rat. In addition, experiments on rodents have revealed that the administration of sabiporide improved cardiovascular function and attenuates organ injury from severe sepsis. However, the development of this drug appears to be discontinued.

Salacetamide is a derivative of salicylic acid. It is analgesic, anti-inflammatory and antipyretic agent.

IVARIMOD is a hepatoprotectant.

FLOTRENIZINE, a diarylmethylpiperazine derivative, is an antihistaminic agent.

Glybuthiazole is a sulfonamide derivative with antihyperglycemic activity, which possesses anti-diabetic properties. It is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells.

Glenvastatin (HR780) is a synthetic HMG-CoA reductase (HMGCR) inhibitor. Like other statins, glenvastatin shows very low systemic bioavailability due to an extensive first pass effect at the intestinal and/or hepatic level. This is a positive trait, since the liver is the target organ for statins. Evidence has been found that glenvastatin protects the vascular endothelium from oxidant stress and inhibits the migration and proliferation of smooth muscle cells. In rabbits, long-term treatment with glenvastatin reduces the plasma cholesterol level, and decreases the liver cholesterol contents. There are no results of clinical trials for glenvastatin.